<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04209504</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00104053</org_study_id>
    <nct_id>NCT04209504</nct_id>
  </id_info>
  <brief_title>Evaluating Hemidiaphragmatic Paralysis With Prolonged Neural Blockade From an Interscalene Brachial Plexus Block</brief_title>
  <official_title>Evaluating Hemidiaphragmatic Paralysis With Prolonged Neural Blockade From an Interscalene Brachial Plexus Block</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective observational study aims to evaluate the incidence of hemidiaphragmatic&#xD;
      paralysis in patients receiving interscalene brachial plexus nerve block with prolonged&#xD;
      neural blockade. English speaking American Society of Anesthesiologists (ASA) 1-3 patients&#xD;
      ages 18-80 receiving prolonged interscalene nerve block will be randomized into 3 groups:&#xD;
      first group receiving a perineural catheter infusing 0.2% ropivacaine; the second group&#xD;
      receiving a single shot injection of 10mL liposomal bupivacaine (Exparel; n=20) plus 5 mL&#xD;
      0.5% bupivacaine and the third receiving 20mL liposomal bupivacaine plus 5mL bupivacaine (to&#xD;
      be determined by the attending anesthesiologist).Primary outcome will be incidence of&#xD;
      hemidiaphragmatic paralysis postoperative day 1 as measured by point of care (POCUS)&#xD;
      ultrasound.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective observational study aims to evaluate the incidence of hemidiaphragmatic&#xD;
      paralysis in patients receiving interscalene brachial plexus nerve block with prolonged&#xD;
      neural blockade. English speaking ASA 1-3 patients ages 18-80 receiving prolonged&#xD;
      interscalene nerve block will be randomized into 3 groups first group receiving a perineural&#xD;
      catheter infusing 0.2% ropivacaine; the second group receiving a single shot injection of&#xD;
      10mL liposomal bupivacaine (Exparel; n=20) plus 5 mL 0.5% bupivacaine and the third group&#xD;
      receiving 20mL liposomal bupivacaine plus 5mL bupivacaine (to be determined by the attending&#xD;
      anesthesiologist). Primary outcome will be incidence of hemidiaphragmatic paralysis&#xD;
      postoperative day 1 as measured by point of care (POCUS) ultrasound. Secondary outcomes&#xD;
      include incidence of hemidiaphragmatic paralysis as measured by point of care ultrasound&#xD;
      (POCUS) in the immediate postoperative period, postoperative day (POD) 1, POD2, and POD3 and&#xD;
      noninvasive measures of pulmonary gas exchange at pre-op, post-op, POD1, POD2, and POD3.&#xD;
      Additionally, the investigators will look at pain scores (scale of 0-10) and opioid&#xD;
      consumption (in oral morphine equivalents) at previously defined time points listed above.&#xD;
      Furthermore, the investigators will record known side effects of interscalene blocks&#xD;
      including hoarseness and Horner's syndrome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 12, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hemidiaphragmatic paralysis - ipsilateral - postoperative day (POD) 1</measure>
    <time_frame>24 hours</time_frame>
    <description>Ultrasound guided evaluation of ipsilateral hemidiaphragmatic paralysis POD1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemidiaphragmatic paralysis - ipsilateral - PACU, POD2, POD3</measure>
    <time_frame>up to 72 hours</time_frame>
    <description>Ultrasound guided evaluation of ipsilateral hemidiaphragmatic paralysis in PACU, POD2, and POD 3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Noninvasive pulmonary measures of gas exchange</measure>
    <time_frame>up to 72 hours</time_frame>
    <description>Noninvasive pulmonary measures of gas exchange</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain scores</measure>
    <time_frame>up to 72 hours</time_frame>
    <description>Numerical Rating Scale (NRS) 11 pain scores (0-10; 0=no pain, 10=worst pain ever) at Post Anesthesia Care Unit (PACU), POD1, POD2, POD3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid consumption</measure>
    <time_frame>up to 72 hours</time_frame>
    <description>Opioid consumption in Oral Morphine Equivalents (OMEs) at PACU, POD1, POD2, POD3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hoarseness</measure>
    <time_frame>up to 72 hours</time_frame>
    <description>Incidence of recurrent laryngeal nerve palsy (subjective)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Horner's Syndrome</measure>
    <time_frame>up to 72 hours</time_frame>
    <description>Incidence of Horner's Syndrome</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Shoulder Surgery</condition>
  <condition>Shoulder Pain</condition>
  <condition>Shoulder Injuries</condition>
  <condition>Shoulder Arthritis</condition>
  <condition>Shoulder Disease</condition>
  <condition>Rotator Cuff Tears</condition>
  <condition>Rotator Cuff Injuries</condition>
  <condition>Rotator Cuff Arthropathy of Left Shoulder</condition>
  <condition>Rotator Cuff Arthropathy of Right Shoulder</condition>
  <condition>Rotator Cuff Repair</condition>
  <arm_group>
    <arm_group_label>Continuous Perineural Catheter</arm_group_label>
    <description>Placement of preoperative continuous perineural catheter using 25 milliliters (mL) 0.5% ropivacaine with 1:400,000k ropivacaine for initial block and 0.2% ropivacaine for continuous infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>10 mL Liposomal Bupivacaine Single Shot</arm_group_label>
    <description>Placement of preoperative single shot using 10mL liposomal bupivacaine (Exparel; n=20) plus 5 mL 0.5% bupivacaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>20 mL Liposomal Bupivacaine Single Shot</arm_group_label>
    <description>Placement of preoperative single shot using 20mL liposomal bupivacaine (Exparel; n=20) plus 5 mL 0.5% bupivacaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Ultrasound</intervention_name>
    <description>Ultrasound guided evaluation of diaphragm ipsilateral to the block side.</description>
    <arm_group_label>10 mL Liposomal Bupivacaine Single Shot</arm_group_label>
    <arm_group_label>20 mL Liposomal Bupivacaine Single Shot</arm_group_label>
    <arm_group_label>Continuous Perineural Catheter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>Local anesthetic (numbing drug)</description>
    <arm_group_label>Continuous Perineural Catheter</arm_group_label>
    <other_name>Naropin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>Local anesthetic (numbing drug)</description>
    <arm_group_label>10 mL Liposomal Bupivacaine Single Shot</arm_group_label>
    <arm_group_label>20 mL Liposomal Bupivacaine Single Shot</arm_group_label>
    <other_name>Liposomal bupivacaine</other_name>
    <other_name>Exparel</other_name>
    <other_name>Marcaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MediPines AGM100 Advanced Respiratory Monitoring System</intervention_name>
    <description>Non-invasive respiratory monitor to measure oxygenation and ventilation parameters</description>
    <arm_group_label>10 mL Liposomal Bupivacaine Single Shot</arm_group_label>
    <arm_group_label>20 mL Liposomal Bupivacaine Single Shot</arm_group_label>
    <arm_group_label>Continuous Perineural Catheter</arm_group_label>
    <other_name>non-invasive respiratory monitor</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients ages 18-80 undergoing shoulder surgery per standard of care.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  English speaking 18-80 year old ASA 1-3 patients&#xD;
&#xD;
          -  Primary shoulder surgery&#xD;
&#xD;
          -  Must live within a 25 mile radius&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ASA 4 or 5&#xD;
&#xD;
          -  Revision shoulder surgery&#xD;
&#xD;
          -  Diagnosis of chronic pain&#xD;
&#xD;
          -  Daily chronic opioid use (over 3 months of continuous opioid use)&#xD;
&#xD;
          -  Inability to communicate pain scores or need for analgesia&#xD;
&#xD;
          -  Infection at the site of block placement&#xD;
&#xD;
          -  Age under 18 years old or greater than 80 years old&#xD;
&#xD;
          -  Pregnant women (as determined by point-of-care serum bHCG)&#xD;
&#xD;
          -  Intolerance/allergy to local anesthetics&#xD;
&#xD;
          -  Weight &lt;50 kg&#xD;
&#xD;
          -  BMI &gt; 40&#xD;
&#xD;
          -  severe pulmonary disease including chronic obstructive pulmonary disease and&#xD;
             restrictive lung disease&#xD;
&#xD;
          -  Suspected, or known addiction to or abuse of illicit drug(s), prescription&#xD;
             medicine(s), or alcohol within the past 2 years.&#xD;
&#xD;
          -  Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the&#xD;
             opinion of the investigator, may interfere with study assessments or compliance.&#xD;
&#xD;
          -  Current or historical evidence of any clinically significant disease or condition&#xD;
             that, in the opinion of the investigator, may increase the risk of surgery or&#xD;
             complicate the subject's postoperative course.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amanda Kumar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>WIlliam M Bullock, MD, PhD</last_name>
    <phone>919-681-6437</phone>
    <email>william.bullock@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amanda Kumar, MD</last_name>
    <phone>919-681-6437</phone>
    <email>amanda.kumar@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Duke University Hospital</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William M Bullock, MD, PhD</last_name>
      <phone>919-681-6437</phone>
      <email>william.bullock@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Amanda Kumar, MD</last_name>
      <phone>919-681-6437</phone>
      <email>amanda.kumar@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Amanda Kumar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>William M Bullock, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeff C Gadsden, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 20, 2019</study_first_submitted>
  <study_first_submitted_qc>December 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2019</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rotator Cuff Repair</keyword>
  <keyword>Shoulder Surgery</keyword>
  <keyword>Hemidiaphragmatic paralysis</keyword>
  <keyword>Interscalene Block</keyword>
  <keyword>Interscalene Catheter</keyword>
  <keyword>Interscalene Liposomal Bupivacaine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shoulder Pain</mesh_term>
    <mesh_term>Joint Diseases</mesh_term>
    <mesh_term>Paralysis</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Rotator Cuff Injuries</mesh_term>
    <mesh_term>Shoulder Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Individual participant data will not be shared; patients will be deidentified and no personal information or medical records used once patient has completed the study.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

